Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India".
Press Release Mar 21 2026
Filed with NSE · · 3 pages · English
Release
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- Press Release Mar 16 2026
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami
- U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
- Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care
Later from Sun Pharmaceutical Industries
- Press Release Mar 27 2026
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Press Release Apr 27 2026
- Organon Cancels First Quarter Earnings Call
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries